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ABSTRACT 
Objective: Combination therapy is recommended for carbapenem resistant Gram negative bacilli (CR GNB) infections. However, limited data exists 
on the clinical effectiveness of antibiotic combinations. The purpose of this study was to evaluate the efficacy of colistin-carbapenem combination 
against CR GNB infection in a clinical study and an in vitro synergy study using Etest. 
Methods: A study was conducted in a tertiary care hospital to evaluate the clinical outcome of patients with CR GNB infections who were treated 
with colistin-carbapenemcombination between January to April, 2013. It was comprised of 33 patients with CR GNB infection. Detection of in vitro 
synergy was performed by Etest for colistin-meropenem combination on five isolates. These isolates were also screened for the resistant genes 
blaOXA-23, blaVIMand blaNDM
Results: 33 CR GNB included Acinetobacterspp. (19), Pseudomonas aeruginosa (7) and Enterobacteriaceae spp. (7). Overall clinical success of 60.6% 
was observed in patients receiving colistin-carbapenem combination therapy. In respiratory infection, the clinical success rate was only 25%, 
whereas in soft tissue infection it was 57.1%. In bloodstream infection 100%  clinical success was observed. All five isolates screened using PCR was 
carrying bla NDM gene, whereas isolate of Acinetobacter baumannii also carried bla
 using single target PCR. 
OXA-23 and blaVIM
Conclusion: We observed low clinical success rate for colistin-carbapenem combination therapy, probably due to indifferent interactions between 
colistin and meropenem against NDM producing strain. In addition, probable pharmacokinetic concern of colistin may have a role to play.  
 gene. Indifferent interactions were observed 
between colistin and meropenem against all five isolates. 
Keywords: Carbapenem resistance, Etest, New Delhi metallo-β-lactamases, Synergy. 
 
INTRODUCTION 
Carbapenems are commonly used to treat severe infections in 
critically ill patients[1]. Unfortunately, Gram-negative bacilli (GNB), 
the most clinically relevant being Acinetobacter baumannii, 
Pseudomonas aeruginosa, Klebsiella pneumoniae and other 
Enterobacteriaceae, are becoming increasingly non-susceptible to 
carbapenems [2]. Carbapenem resistance is predominantly 
conferred by carbapenemases, such as oxacillinase (OXA)-type 
enzymes and metallo-β-lactamases (MBLs) of Imipenemase (IMP), 
Verona Italy metallo-β-lactamases (VIM) and New Delhi metallo-β-
lactamases (NDM) types, and serine carbapenemases of Klebsiella 
pneumoniae carbapenemases (KPC) type [2]. Although all the 
resistant mechanisms are being increasingly identified worldwide, 
there are some clear endemic areas, such as NDM producers in India 
[3]. 
Carbapenem resistance often show concurrent carriage of additional 
resistance determinants to many other classes of antimicrobials 
such as quinolones and aminoglycosides. Therefore, therapeutic 
options for these infections are extremely limited and with that 
clinicians have returned to the use of colistin (COL) [2]. However, 
the clinical use of COL is hindered by side effects, mainly 
nephrotoxicity, in addition to unclear optimal dosing. In order to 
improve clinical success, various combination therapies have been 
used with COL. One of the antibiotic classes most commonly used in 
combination with COL is the carbapenem[1].  
The combination of COL and carbapenem against Gram negative 
bacilli is supported in vitro by high synergy and bactericidality rates, 
with low antagonism and less resistance development. However, 
reported strain to strain variation suggests that individualized or 
centre based synergy testing is of value [1].  
The aim of this study was to report our experience of clinical 
effectiveness of COL-carbapenem combination against carbapenem 
resistant Gram negative bacilli (CR GNB) infections including in vitro 
synergy testing of representative strains using Etest.  
MATERIALS AND METHOD 
The study was conducted at a 750 bedded tertiary care hospital in 
Mumbai, India. This study was approved by the Institutional 
Scientific and Ethics Board (ISEB) of the hospital. General consent 
was taken from all the patients for testing required for diagnosis and 
use of results for epidemiological or research based purposes. 
The enrolled patients  were hospitalized patients with CR GNB infections 
who were treated with COL- carbapenem combination between January 
2013 and April 2013.160 to 240 mg (2 to 3 MIU) of colistimethate 
sodium (CMS) per 8 or 12 h was administered and doses were adjusted 
according to the renal functions along with 1g dosing of carbapenem 
every 8 h. Exclusion criteria were as follows: Administration of COL-
carbapenem combination as empirical treatment or for infections 
involving organisms other than CR GNB and patients for whom the 
duration of combination treatment was < 48 h. 
GNB isolates obtained from clinical specimen received for cultural 
studies during the study period were identified as carbapenem 
resistant by imipenem and/or meropenem resistant results from 
routine laboratory test system (Vitek 2; bio Merieux). Antibiotic 
susceptibility was interpreted as per criteria published by CLSI [4]. 
Susceptibility of tigecyclin was determined by the use of minimum 
inhibitory concentration (MIC) breakpoints approved by the US 
Food and Drug Administration (US-FDA) [5]. For COL, break points 
proposed by a European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) were used because relevant break points were not 
available from CLSI [6]. 
Carbapenemase production was detected using modified Hodge’s 
test (MHT) and MBLs production using Ethylene-diamine-tetra-
acetic acid (EDTA) disk synergy test, as described [7]. 
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One representative isolate from each genera comprising 
Acinetobacter baumanii, Pseudomonas aeruginosa, Klebsiella 
pneumoniae, Escherichia coli and Enterobacter cloacae was selected 
based on susceptibility profile. DNA was extracted from these 
strains by heat boil method and were screened for the resistant 
genes blaOXA-23, blaVIMand blaNDM by single target PCR using 
previously published primers, OXA-23, Oxa-23-F 5’-
GATCGGATTGGAGAACCAGA-3’/ Oxa-23-R 5’-ATTTCTGACCG 
CATTTCCAT-3’; VIM, Vim-F 5’-GATGGTG TTTGGTCGCATA-3’/ Vim-R 
5’-CGAATGCGCAGCACCAG-3’; NDM-F 5’-GGTTTGGCGATCT 
GGTTTTC-3’/ NDM-R 5’-CGGAATGGCTCATCACGATC-3’[8-10].  
Further, in vitro synergy between COL and meropenem (MER) 
against these strains were determined using Etest. Mueller-Hinton 
agar plates (HiMedia, Mumbai, India) were used for Etest MIC and 
synergy testing. The MICs of COL and MER were determined using 
Etest strips (bioMerieux). Synergy screening was performed using a 
method employing two Etests applied at right angles to each other, 
as described [11]. The following formulas were used to calculate the 
fractional inhibitory concentration (FIC) index: FIC of MER = MIC of 
MER in combination/MIC of MER alone; FIC of COL = FIC of COL in 
combination/MIC of COL alone; FIC index = FIC MER + FIC of COL. 
Synergy is defined as an FIC index of ≤0.5. Indifference is defined as 
an FIC index of >0.5 but of ≤4. Antagonism is defined as an FIC index 
of >4[11].  
Amongst the 19 isolates of Acinetobacter spp., 18 were Acinetobacter 
baumannii and 1 was identified as Acinetobacter junii. 
Enterobacteriaceae spp. (7) included Klebsiella pneumoniae (4), 
Escherichia coli (2), and Enterobacter cloacae (1). Susceptibility 
profile of these isolates is given in Table 2, 3 and 4. With MHT 
carbapenemase production was detected in 31/33 (93.9%) isolates, 
whereas EDTA-disk synergy test detected MBL production in 30/33 
(90.9%) isolates. 
Data recorded for each patient included the following: 
demographic details, associated co-morbidities, previous 
antimicrobial regimens, site of infection, causative pathogen and 
length of stay. Only single clinically significant isolate from the 
patient was included. Outcome at the end of treatment was defined 
as successful (partial or complete improvement of signs/symptoms 
of infection or positive microbial response in terms of sterile culture 
results post or during the treatment), or failure (no improvement or 
deterioration of signs/symptoms of infection or negative microbial 
response in terms of persistent positive culture results with the 
same organism 3 days after initiation of antibiotic therapy). Final 
disposition was defined as death, discharged during illness or 
transferred to ward or discharged. 
RESULTS 
A total of 33 patients received COL-carbapenem combination 
therapy for CR GNB infections during the study period. Patient and 
pathogen characteristics are recorded in Table 1. All patients had 
received other antimicrobial agents prior to acquiring infection by 
CR GNB. The total number is more than 100%, since most of the 
patients received more than one antimicrobial agent. 
Table 1: Characteristics of patients treated with COL-
carbapenem combination 
Variable n (%) 
Demographics  
 Age [median (range)] 58 yrs (1 month - 
86 yrs) 
 Sex (male) 20 (60.6) 
Comorbidity  
 Heart dysfunction 8 (24.2) 
 Malignancy 7 (21.2) 
 Diabetes Mellitus 9 (27.3) 
 Hyper tension 12 (36.4) 
 Chronic renal failure 7 (21.2) 
Admission to ICU 31 (93.9) 
Prior surgery 3 (9.1) 
Prior antibiotic use 33 (100) 
 BL/BLI 26 (78.8) 
Carbapenem 18 (54.5) 
 Aminoglycosides 5 (15.2) 
Colistin 4 (12.1) 
Fluoroquinolones 3 (9.1) 
Tigecyclin 1 (3.0) 
Prior hospitalization 9 (27.3) 
Type of infection  
 Respiratory infection 12 (36.4) 
 Bloodstream infection 12 (36.4) 
 Soft tissue infection 7 (21.2) 
 Urinary tract infection 2 (6.0) 
Pathogens  
Acinetobacter spp. 19 (57.6) 
Pseudomonas aeruginosa 7 (21.2) 
Enterobacteriaceae spp. 7 (21.2) 
Time to develop infection with CRGNB (days) 
[mean ± SD (range)]  
16.0 ± 22.57 (0 to 
127) 
Duration of hospitalization (days) [mean ± SD 
(range)] 
42.6 ± 31.49 (12 
to 143) 
Note: BL/BLI - β-lactam/β-lactamase inhibitor, ICU - intensive care 
unit, SD - Standard deviation. 
 
All five representatives isolate screened using PCR analysis were 
found to be carrying blaNDM gene, whereas isolate of Acinetobacter 
baumannii also carried blaOXA-23 and blaVIM 
 
genes. Results of in vitro 
synergy testing using Etest for COL and MER combination against 
these five representative isolates are shown in Table 5. All isolates 
showed indifferent results. 
Table 2: Susceptibility profile of Acinetobacter spp isolates 
 Acinetobacter spp. 
Antimicrobial agent MIC range mg/l MIC50 MICmg/l 90 % Sensitivity mg/l 
Imipenem* ≥16 ≥16 ≥16 0 
Meropenem* ND - - - 
Amikacin* ND - - - 
Tobramycin* ≤1 to ≥16  8  ≥16 42 
Gentamycin* ≤1 to ≥16  8  ≥16 5 
Colistin** ≤0.5  ≤0.5 ≤0.5 100 
Tigecyclin*** ≤0.5 to 4 2 4 47 
Ciprofloxacine* ≥4 ≥4 ≥4 0 
 
Overall in-hospital mortality of 42.4% (14/33) was observed in this 
study. Three patients died because of the reasons unrelated to 
infection and attributed mortality of the infection was found to be 
33.3% (11/33). Successful clinical outcome of the infection was 
observed in 20 out of 33 patients (60.6%). A total of 11 out of 13 
patients whose infections were unresponsive to therapy died 
andtwo were discharged during illness. Table 6 presents the clinical 
response associated with the site of infection and the causative 
pathogen for patients treated with COL-carbapenem combination. 
COL-MER combination (16/24 successful cases) was more 
commonly used compared to COL-Imipenem combination (4/9 
successful cases). 
DISCUSSION 
Infections caused by CR GNB constitute a major challenge for 
current medical practice due to limited therapeutic options for these 
infections and there are no established guidelines for their 
management.  
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Many CR GNB isolates are only susceptible to colistin; however, 
colistinpresents some drawbacks, which have discouraged its use in 
monotherapy. In this context, along with strong pre-clinical evidence 
of benefit in combining antimicrobials against CR GNB, the clinical 
use of combination therapy has been raised as an interesting 
strategy to overcome these potential limitations of a single 
agent[12]. The commonly used combination of COL, especially COL 
and MER against GNB is supported in vitro by high synergy and 
bactericidality rates[1]. Nevertheless, clinical studies validating in 
vitro findings are limited. 
 
Table 3: Susceptibility profile of Pseudomonas aeruginosa isolates 
Pseudomonas aeruginosa 
Antimicrobial agent MIC range mg/l MIC50 MICmg/l 90 % Sensitivity mg/l 
Imipenem* 4 to ≥16 8  ≥16 0 
Meropenem* 8 to ≥16  ≥16  ≥16 0 
Amikacin* 16 to ≥64 ≥64 ≥64 14 
Tobramycin* ≥16  ≥16  ≥16 0 
Gentamycin* ≥16  ≥16  ≥16 0 
Colistin** ≤0.5 to 3 ≤0.5 ≤0.5 100 
Tigecyclin*** NA - - - 
Ciprofloxacine* ≥4 ≥4 ≥4 0 
 
Table 4: Susceptibility profile of Enterobacteriaceae spp isolates 
Enterobacteriaceae spp. 
Antimicrobial agent MIC range mg/l MIC50 MICmg/l 90 % Sensitivity mg/l 
Imipenem* 2 to ≥16 4  ≥16 0 
Meropenem* 4 to ≥16 ≥16 ≥16 0 
Amikacin* 16 to ≥64 32 ≥64 42 
Tobramycin*  ≥16  ≥16 ≥16 0 
Gentamycin* ≤1 to ≥16  ≥16  ≥16 28 
Colistin** ≤0.5  ≤0.5 ≤0.5 100 
Tigecyclin*** ≤0.5 to ≥8 2 ≥8 57 
Ciprofloxacine* ≥4 ≥4 ≥4 0 
Note: MIC, Minimum inhibitory concentration;  MIC50, MIC (mg/l) required to inhibit the growth of 50% of organism, MIC90
 
, MIC (mg/l) required to 
inhibit 90% of organism, MICs (mg/l) were determined by broth dilution method, * MICs were interpreted in accordance with the CLSI, ** MICs 
were interpreted in accordance with EUCAST, *** MICs were interpreted in accordance with US-FDA, ND – Not Done, NA – Not Applicable 
Table 5: MER and COL Etest MICs and synergy testing by Etest 
Clinical Isolate MIC of 
MER 












A. baumannii ≥32 24 0.75 0.125 0.094 0.75 1.5 ind 
P. aeruginosa ≥32 ≥32 1 3 3 1 2ind 
K. pneumoniae 8 8 1 0.25 0.25 1 2ind 
E. coli 4 4 1 0.125 0.125 1 2 ind 
Enterobacter cloacae 4 3 0.75 0.25 0.19 0.76 1.51 ind 
Note: FICI – Fractional inhibitory concentration index, ind – indifference 
 
Table 6: Outcome of patients treated with COL-carbapenem combination associated with type of infection and causative pathogen 















Acinetobacter spp. 19 11(57.9) 3/9 (33.3) 4/4 (100) 4/6 (66.7) - 
Pseudomonas aeruginosa 7 3 (42.9) 0/3 (0) 2/2 (100) 0/1 (0) 1/1 (100) 
Enterobacteriaceae spp. 7 6 (85.7) - 6/6 (100) - 0/1 (0) 
Total 33 20 (60.6) 3/12 (25) 12/12 (100) 4/7 (57.1) 1/2 (50) 
 
In this study, we examined the clinical effectiveness of COL-
carbapenem combination against CR GNB infection in 33 
hospitalized patients. On evaluating the patient characteristics it was 
observed that all the patients were exposed to multiple antibiotics, 
93.9% were admitted to ICU, and overall long hospital stay. These 
are some of the risk factors making them more vulnerable to 
acquiring CR GNB infection [13, 14]. These risk factors along with 
underlying comorbidities indicated the patients group in the present 
study to be critically ill. Looking at the susceptibility profile of the 
clinical isolate. It could be ascertained that there were very few 
treatment options for serious infection caused by CR GNB. 90.9% 
positivity of EDTA-disk synergy test suggested that carbapenem 
resistance was largely conferred by MBLs in the present study 
cohort. 
Amongst COL-carbapenem combination, MER was more preferred 
over imipenemin combination therapy. Hence, COL-MER 
combination was used in Etest, to evaluate it's in vitro effectiveness 
against CR GNB. All isolates selected for in vitro sensitivity testing 
were found to be NDM producers, whereas clinical isolate of 
Acinetobacter baumannii carried multiple carbapenem resistance 
genes along with NDM. In vitro synergy testing showed indifferent 
interactions between COL and MER against these isolates. Findings 
of our study are in accordance with recent observations of time-kill 
experiment demonstrating no bactericidal effect of COL-MER against 
VIM- and NDM- producing Klebsiella pneumonia [15].  
They are also in partial agreement with the previous report showing 
no marked synergy or borderline synergy of colistin in combination 
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with carbapenem against CR Acinetobacter baumannii isolates 
producing OXA-23[16].  
Although no synergistic activity was demonstrated against our 
isolates by COL-MER combination, all isolates were sensitive to 
colistin with MIC of COL as low as ≤0.5mg/l (except one Pseudmonas 
aeruginosa isolate from respiratory infection, Colistin MIC-3 mg/l). 
Despite this fact clinical success of 60.6% was observed in patient 
receiving COL-carbapenem combination therapy against CR GNB 
infections. Probable pharmacokinetic (PK) concerns of colistin might 
be related to the failure to improve infections caused by sensitive 
microorganisms. In 2010,Imbertiet al. reported plasma colistinCmax
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